Connect with us

Health Care

Nanorobotics – Yossi Keret

Published

on

The CEO Mindset - Yossi Keret is the Chief Executive Officer of Nanorobotics

Yossi Keret is CEO of Nanorobotics, a disruptive startup in biotech, where he leads management, fundraising, financing, business development, strategic negotiations, and other company activities. In addition, he is a board member of Wize Pharma. Prior to joining Nanorobotics, Yossi worked with high-tech, biotech, and cleantech companies reorganizing and preparing them for public or private fundraising. He is the former CEO and board member of Weebit Nano, and the  former global CFO of the following companies: Eric Cohen Books & Burlington English, Daimler Financial Services, Pluristem, M.L.L. Software and Computer Industries.

Yossi’s accomplishments include leading a successful IPO in the Australian Stock Exchange as part of his CEO role; leading the successful development of ReRAM (memory) from Rice University to 40 Nano working cells; taking a major part in a successful Initial Public Offering (IPO) in NASDAQ; leading private equity raising (PIPE) for public companies; possessing in-depth familiarity with accounting regulations in Israel, US GAAP and IFRS; and taking a major part in M&A discussions and implementation. Yossi is a certified public accountant (CPA). He received his B.A. in economics and accounting from Haifa University in Haifa, Israel. He lives in Israel with his wife and three children.

What’s your journey in becoming a CEO?
I come from a financial background, both in terms of my education and my career. I was the CFO of several companies in different industries. In 1996, I took a company public on NASDAQ for the first time. I am a math person, but I wanted to lead businesses, which brought me to where I am today. I was the CEO of Weebit Nano (ASX: WBT) where we developed and commercialized a technology for the next generation Reram memory. I led a successful IPO on the ASX, the Australian Stock Exchange. I was fascinated by the nanorobotics technology which, like Weebit technology, came from the same laboratory of Prof. James Tour at Rice University. It was my dream to take this technology further and in 2019, together with my colleagues, we have founded Nanorobotics and I became its CEO and Executive Director.

Tell us a bit about your business and how you are commercializing?
This is a very exciting technology. Since it is a platform, I initially had to focus on one area. Once I assembled my team, we decided to focus on molecular therapy for cancer treatment. The journey is akin to drug development, e.g. in vivo studies followed by toxicology and GLP validation. I estimate in two years we’ll conclude these studies. We’ll then start human trials. Nanorobotics has one lead program: Non-Muscle Invasive Bladder Cancer.

In addition to cancer therapy, our nanorobotics platform has other uses such as antibacterial effects against highly resistant bacteria, dermato-cosmetics, ophthalmology, and others. Once our nanorobotics platforms will gain momentum, I will look to out-licensing agreements with big pharma and medtech companies. At that point, we’ll be able to form strategic partnerships through which we’ll attain upfront fees and milestones payments. In 4-5 years, I hope to achieve full commercialization.

How are you managing with the current COVID-19 pandemic on both business and personal front?
Our in vivo research is being conducted in Texas, U.S., a state that has been largely affected by the pandemic. Many labs and institutions shut down, and only now are reopening again. I sincerely hope that this shutdown will not significantly impact our R&D plans, and we can reach our milestones soon. Moreover, there are several travel restrictions that have hampered our ability to meet with investors for fund raising. We, similar to others, have moved to Zoom investor meetings and we hope to continue our successful seed fund raising.

Spending less time on the air and more time on the ground, I find that I’m having a great time with my family – my wife, three kids, and two dogs.

What’s the most exciting thing about running your business?
I lost my sister to cancer at a young age. It’s deeply meaningful for me to work in this field, to be at the forefront of this medical revolution. It moves me personally that our technology may be able to bring remedy to cancer patients, targeting only the cancerous tissues without damaging the rest of their bodies, giving them a second chance at life.

I am also excited to work with a great team – they all have scientific or medical backgrounds and I enjoy interacting with them on a daily basis. We are all visionaries who think and see the next thing. That’s what drives us today, and I hope it will continue to drive us all the way to a successful tomorrow.

How do you measure success?
I’m a very organized and KPI-driven person, even on a daily basis. I lock my gaze on my target and determine my success through measurable outcomes. Our mission at the end of the day is to bring safe and effective drugs to the market, bringing hope to countless patients, some with poor prognosis. And this, I hope, will translate to maximum return on investment for my shareholders.

What do you think is the most important quality of being a CEO of a listed company?
Seeing the big picture, keeping an immense vision in sight, and not miss the forest for the trees.  Executing great corporate culture in which trust and integrity are key elements. Another quality is the ability to communicate the progress to shareholders, particularly at a public company. Sometimes, progress in biotech firms is slow paced and not all the pieces of the puzzle are in place. I see myself as someone who needs to overcome this gap and make the necessary effort to sustain momentum.

What is your favorite book?
Think and Grow Rich is my favorite book of all time. It asks, “what makes a winner?” and offers a “Law of Success” philosophy that has shaped my business and world view. I’ve tested and demonstrated the soundness of this formula many times, at every company I worked for. Suffice it to say I’ve always managed to keep my investors and shareholders happy.

What about yur favorite movie or TV show?
I also like to go to movie theaters, but they have now been shut down since early March and we don’t know when they will reopen. So instead, I am now watching a great TV series called “The Rain.” It is about a virus that wipes out almost everyone in Scandinavia. The show’s two protagonists search for a safe place as well as a cure. It’s a good watch as it relates to our current-day situation as well as medical advances.

What message do you want to send to our readership in Asia?
Nanorobotics is developing a technology that will reshape medical treatment. I believe it has the potential to revolutionize the field of molecular therapy. As we are now a global village, my hope is that in a post-COVID-19 world, all nations and groups will work closer together and cooperate more.

How can people connect with you?
Yossi Keret, LinkedIn
Email:
Mobile: +972-54-8008404
Website: http://nanorobotics.tech/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Nanorobotics Executive Team – Pictured from left: Dr. David Izhaky (Chief Technology Officer) and Yossi Keret (Chief Executive Officer)

About Nanorobotics:
Nanorobotics has developed a novel nanorobotic-platform – using all-new rotor-propelled mechanical Molecular NanoMachines (MNMs). The MNMs drill and tunnel through the membranes of targeted individual cancer cells and promptly induce death, in addition to being capable of administering drugs. The patented Nanorobotics technology ushers in a new, noninvasive treatment frontier for cancer, bringing surgery to the molecular level.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health Care

$5M cap raise gives MYQ a further boost in trillion dollar health tech market

Published

on

$5M cap raise gives MYQ a further boost in trillion dollar health tech market

There has been a strong investor focus this year on companies that provide stay-at-home type services such as Amazon (NASDAQ: AMZN) – its shares have increased from about US$1600 to a high of US$3550 in the last 12 months with the majority of those gains occurring since the emergence of COVID-19.

Looking more broadly at the technology sector, it has outperformed the market over the past 12 months, providing investors with a total return of 56%. Compare this to the S&P 500’s total return of 22.5% over the same period and you get a sense of how this sector has boomed in the face of the pandemic.

Australia measures its tech stock performance through the S&P/ASX All Technology Index, which was launched on 24 February this year.

This index, which features 58 of Australia’s leading and emerging technology companies, has followed a similar trajectory to the NASDAQ adding $33 billion in value in three months.

One reason is the accelerated uptake of technology and online activities, such as healthcare services.

This includes the uptake of health tech services such as those offered by the $156M capped MyFiziq (ASX: MYQ), which has started the process of a NASDAQ listing.

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone privately and accurately.

MYQ last week appointed Ladenburg Thalmann & Co. Inc. to facilitate the listing which would open up a huge market segment to this health tech provider.

As a member of the New York Stock Exchange for more than 135 years, Ladenburg’s breadth of experience across financing and capital markets will be invaluable to MyFiziq as it goes through a period of rapid expansion.

With MyFiziq’s business involving corporate transactions with a multitude of players in the health and wellness sector and significant investment required for research and development purposes, the proposed NASDAQ listing couldn’t have come at a better time.

Access to capital markets that are very much attuned to the tech and biotech industries is a distinct advantage, highlighted by the fact that many merger and acquisition transactions that have occurred among MyFiziq’s peers in the last 12 months have been NASDAQ-listed entities.

The biggest health tech M&A in recent times has been Teledoc’s $18.5BN acquisition of Livongo that will create a leader in consumer-centred virtual health care.

To assist the listing as well as further roll out of the MYFiziq app is the completion of a $5 million placement to sophisticated and institutional investors. The placement was priced at $1.20 and included 1:1 free options for placement participants at a strike price of $1.60 and a 3 year expiry date.

Commenting on this development, chief executive Vlado Bosanac said, “I am very pleased with the support we have received for the placement.

‘’We worked closely with Evolution Capital and the list of institutional and high net worth investors they brought to the table.

“The offer closed substantially oversubscribed, demonstrating significant investor interest in the company.

‘’With the current partner rollouts underway and MyFiziq starting to generate revenue, we are now in a position where the company is unlikely to need additional capital outside of any strategic investment opportunities currently being considered or the proposed NASDAQ listing.

‘’This new capital will assist the company in more rapid expansion of our team and the ability to assist our partners in expediting their go to market timelines.”

MyFiziq’s shares were trading at 28 cents two months ago, indicating that the strike price for the capital raising represents a 330% premium to its share price in August.

MyFiziq’s ability to complete a heavily oversubscribed capital raising at a premium price is an endorsement of both the company’s operational future and management’s ability to continue to successfully execute on its growth initiatives.

The raise was an astute move by management to remain on the front foot in positioning the group to engage in its own corporate initiatives, including the collaboration with players in adjacent industries, something that has been a hallmark of the group’s success in 2020.

Some of those collaborations include a potentially company-making deal with Nexus-Vita Singapore, a health monitoring and management technology company that will guarantee MYQ minimum annual revenue of US$3,5M (AU$4.99M) per annum, from the date of commercial launch of its app.

MYQ will work with Nexus to release the app in January 2021.

MYQ has hit several milestones, including an agreement with Bearn LLC targeting over 25 million users, commencing work with Biomorphik and signing its first Binding Term Sheet to expand the newly developed CompleteScan platform capabilities with Asia Pacific corporate wellness platform WellteQ into the $10 trillion global telehealth, corporate wellness and insurance market.

MYQ’s company’s current $150M market cap could prove to be just the beginning for the company – especially ahead of a NASDAQ listing and wider exposure to US investors.

Continue Reading

Health Care

VIP Gloves (ASX:VIP) – Chen Wee Min

Published

on

The CEO Mindset - Chen Wee Min is the Executive Director and Member of the Executive Committee (EXCO) of VIP Gloves (ASX:VIP)

Chen Wee Min is the Executive Director and Member of the Executive Committee (EXCO) of VIP Gloves (ASX:VIP), a wholly-owned subsidiary of VIP Gloves Limited which was established in 2016 to manufacture nitrile disposable gloves from its plant located in Selangor, Malaysia. Currently its products are sold to local and overseas distributors under original equipment manufacturer (OEM) basis.

What’s your journey in becoming a CEO?
I started-off my journey from simple beginnings hailing from the fringes of Kuala Lumpur. I had to prematurely end my education at Year 6 to take care of my family.

To help support the family, I became an apprentice tool maker and worked my way through rank and file to eventually becoming a metal stamping sub-contractor for Auto Parts Electrical appliances and steel related products.

Eventually, I decided to work with my brother in Keng Lek Engineering which was in the business of designing, fabrication and building of conveyor lines for rubber glove industries. After learning the tricks of trade, I decided to take the road less travelled and seized the opportunity to start KLE Products Sdn Bhd (KLE) with 2 other likeminded entrepreneurs.

As you would expect, it was ambitious and no easy feat to build KLE from the ground up. It was especially difficult in securing funding to scale up the business further among private investors.

As such, I quickly seized the opportunity in 2015 when it presented itself to inject KLE into ASX the listed-company, formally known as Voltage IP Limited, which enabled the company to grow into the position it is today.

Nevertheless, I can’t attribute the Company’s position today solely on my decisive actions alone as its been collective effort of my team to which I have been fortunate and blessed to be working with.

Tell us a bit about your business and how you are commercializing?
We started off with KLE which manufactured rubber dipping equipment for prominent Malaysian and International Glovemakers which include Top Glove, Hartalega, Ansell and so on.

As a natural progression thereafter, I made the bold decision to foray into the manufacturing of gloves in March 2016 as to seize the growth opportunity. We have since slowly tapered-off KLE business dealings and have concentrated our efforts into this glove manufacturing venture.  We presently have 4 glove lines (2 single-former lines & 2 double-former lines) in and we intend to rollout an additional 4 single-former lines progressively over the next 18 months which would enable us to achieve our next production output milestone of 1 bil pieces per annum.

How are you managing with the current COVID-19 pandemic on both business and personal front?
We are fortunate to be somewhat shielded during this current COVID-19 pandemic given gloves are essential Personal Protective Equipment (PPE) product during pandemics as seen in the past. In fact, the current glove market demand is currently on an exponential upswing given the global supply shortages being plagued by industry.

On the financial front, we are well positioned to ride this upswing as our sales are buoyant and the sale and leaseback (land & building) will further strengthen to our cash position.

On the personal front, it has been especially psychologically difficult navigating the business during the course of this pandemic especially during the imposition of the Movement Control Order in Malaysia whereby there were times I had to remotely managed the operations given it categorised as ‘essential services’ sector.

What’s the most exciting thing about running your business?
I would say the most exciting thing would be the managing of the daily challenges in my business. I yearn for these challenges and I take them head on with positivity.

How do you measure success?
I am strong believer that any business no matter the scale is underpinned by the people who work under it. Hence, my employees’ satisfaction is my ultimate measure of success.

What do you think is the most important quality of being a CEO of a listed company?
Being a good listener and as such to resolve problems if its within my means.

What is your pastime?
I like spending my pastime with my love ones.

What message do you want to send to our readership in Asia & Australia?
I would like to make a clear distinction here for our investors and soon to be investors that gloves usage is expected to remain prevalent post Covid-19. Given the unprecedented times we are in, I believe glove usage will be become a daily part of our lives moving forward and its uptake in usage will traverse across all industries given its an essential PPE and OHS (Occupational Health and Safety).

This trend is expected to remain even after the vaccine is out as the need for workers to work in a safe environment will remain prevalent. The best example of this is the beverage and hospitality industries where the increased use of gloves has been noticeable.  Another public place where the use of gloves has been more visible is in airports.

OHS will become as important to industry profit margins as carbon emissions.  Commerce now works in a global cycle.  What is good or bad for one will be an issue for all participants of global industries.

I also would like to take this opportunity to extend my upmost appreciation and thankfulness to all our customers, shareholders and not forgetting employees who have stuck through with us throughout journey.

How can people connect with you?
Email:

Company Website: https://www.vipglove.com.my/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Health Care

Q&A With StockPal – Dimerix (ASX:DXB)

Published

on

Q&A with StockPal - Dr. Nina Webster, CEO and MD of Dimerix (ASX:DXB)

Watch Dr. Nina Webster, CEO and MD of Dimerix (ASX:DXB) and Jared Sim, Editor-in-Chief and Co-Founder of StockPal in this engaging Q&A with the following questions:

0:10 – What is your business about?
0:47 – How did your company cope with the COVID-19 pandemic?
1:19 – What is your current development focus?
2:10 – What is the size of your potential target markets?
3:33 – What is your firm’s competitive advantage?
4:16 – How are you currently engaging with your investors?

Visit Dimerix’s website to learn more about their story:

https://dimerix.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Recent Posts

Categories

Trending

  • Market News1 day ago

    Monday Movers – Top 10 ASX Companies Today

  • Market News3 hours ago

    Tuesday’s Top 10 ASX Companies

  • Market News1 week ago

    Tuesday’s Top 10 ASX Companies

  • Market News1 week ago

    Monday Movers – Top 10 ASX Companies Today

  • Market News2 weeks ago

    Tuesday’s Top 10 ASX Companies

  • Market News2 weeks ago

    Thursday’s Top 10 Companies On The ASX

  • Market News3 weeks ago

    Thursday’s Top 10 Companies On The ASX

  • Market News3 weeks ago

    Tuesday’s Top 10 ASX Companies